IRLAB launches Phase Ib Trial of IRL757 for Parkinson’s patients with Apathy
The multicenter study will enroll 75 patients across 16 sites in Germany, Bulgaria, Poland, and Spain
The multicenter study will enroll 75 patients across 16 sites in Germany, Bulgaria, Poland, and Spain
NouvNeu001 is the world’s first allogeneic iPSC-derived cell therapy for Parkinson’s disease to receive this designation
Prasinezumab is a potential first-in-class anti-alpha-synuclein antibody, targeting a known biological driver of Parkinson’s disease progression
New trontinemab data continue to support rapid and deep, dose-dependent reduction of amyloid plaques in Phase Ib/IIa Brainshuttle AD study
Subscribe To Our Newsletter & Stay Updated